The National Institute for Health and Clinical Excellence (NICE): How Does It Work and What Are the Implications for the U.S.?
Image
Authors: Sorenson, C; Drummond, M; Kanavos, P; and McGuire, A.
A study commissioned by the National Pharmaceutical Council examines key learnings from the U.K.'s National Institute for Health and Clinical Excellence (NICE), the organization that provides guidance to the National Health Service on the clinical and economic effects of various medical treatments. The study's authors, Dr. Michael Drummond and co-authors at the London School of Economics, provide an overview of NICE and its operations and consider the implications for comparative effectiveness reviews in the United States. The study is broken out into four parts:
- Part 1 entails a non-technical overview of NICE, encompassing its governance and organization, topic selection procedures, evidence requirements and assessment methods, and guidance dissemination and implementation.
- Part 2 provides an in-depth investigation of evidence requirements and assessment methods.
- Part 3 involves an analysis of public comments on NICE submitted to the House of Commons Health Select Committee, focusing on key stakeholder perspectives on the appraisal process and broader NICE operations.
- Part 4 examines NICE procedures and standards in the context of the U.S. landscape, and identifies those factors or forces unique to the U.S. marketplace, in comparison to the U.K. and other EU Member States, where applicable.